SEC Form 4 · accession 0001209191-15-022573
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacob j Plattner
Officer — Senior VP, Research
Period of report
Mar 2, 2015
Accepted (ET)
Mar 4, 2015 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 2, 2015 | S | 6,475 | $43.9869 | D | 45,000 | I | See Footnote |
| Common StockF4,F3 | Mar 2, 2015 | S | 400 | $44.6025 | D | 44,600 | I | See Footnote |
| Common Stock | holding | — | — | — | 5,020 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.44 to $44.41, inclusive.
- F3These shares are held by Jacob & Jeanne Plattner Trust U/A 7/17/04, Jacob Plattner & Jeanne Plattner, Trustees.
- F4The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $44.65, inclusive.